Top Markets
Coin of the day
Immunovant, Inc. Immunovant, Inc.

Immunovant, Inc.

IMVT
Rang in Aktien #2340
Immunovant, Inc. is a biopharmaceutical firm in the clinical development phase,... Immunovant, Inc. is a biopharmaceutical firm in the clinical development phase, dedicated to advancing novel monoclonal antibody therapies for the treatment of various autoimmune conditions. The company's primary focus is batoclimab, a pioneering, fully human monoclonal antibody. This antibody is engineered to specifically target and block the neonatal fragment crystallizable receptor (FcRn), a key mechanism in certain autoimmune diseases. Batoclimab is currently undergoing Phase IIa clinical evaluations for treating both myasthenia gravis and thyroid eye disease. Additionally, it has commenced Phase II clinical studies for patients suffering from warm autoimmune hemolytic anemia. Established in 2018, Immunovant operates from its headquarters in New York, New York, functioning as a subsidiary under the umbrella of Roivant Sciences Ltd.
Aktienkurs
$43.42
Marktkapitalisierung
$8.96B
Veränderung (1 Tag)
0.23%
Veränderung (1 Jahr)
191.61%
Land
US
Handel Immunovant, Inc. (IMVT)

Kategorie

Kursverlauf für Immunovant, Inc. (IMVT)
Höchster Schlusskurs: $42.51 am 2026-08-01

Niedrigster Schlusskurs: $9.88 am 2019-06-01
Kursverlauf der Aktie von Immunovant, Inc. von 2019 bis 2026
Jährliche Kursentwicklung
Jahr Leistung
2026 (TTM) 8.62%
2025 -7.38%
2024 -34.45%
2023 163.89%
2022 99.44%
2021 -84.02%
2020 273.47%
2019 0.00%
Aktienkurs vergleichbarer Unternehmen oder Wettbewerber
Unternehmen Aktienkurs Veränderung 1J% Land
$553.23 42.24%
US
$1.02K 50.35%
NL
$157.70 522.09%
US
$122.47 -12.71%
AU
$772.27 8.67%
CH